Norges Bank Glycomimetics Inc Transaction History

Norges Bank

  • $716 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 10, 2021
SELL
$2.69 - $4.24 $784,673 - $1.24 Million
-291,700 Closed
0 $0
Q3 2020

Nov 12, 2021
BUY
$3.07 - $5.0 $895,519 - $1.46 Million
291,700 New
291,700 $896,000
Q3 2020

Nov 10, 2020
SELL
$3.07 - $5.0 $1.25 Million - $2.03 Million
-405,594 Closed
0 $0
Q2 2020

Aug 13, 2021
BUY
$2.06 - $3.76 $835,523 - $1.53 Million
405,594 New
405,594 $1.53 Million

Others Institutions Holding GLYC

# of Institutions
36
Shares Held
17.8M
Call Options Held
0
Put Options Held
0
View Full List

About GLYCOMIMETICS INC

GLYC Quotes by TradingView
  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $16.3M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email